• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 02, 2024 at 12:02: PM
via Daiichi Sankyo and MSD (Merck and Co.) have announced the dosing of the first subject in the Phase III IDeate-Lung02 clinical trial of ifinatamab deruxtecan (I-DXd) in people with relapsed small cell lung cancer (SCLC).

article source
 

<



Similar threads

cafead
Navigating the AI &#039;hype cycle&#039;: Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo-Merck&#039;s &#039;guided-missile&#039; cancer drug meets main goal in late-stage trial
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial
Replies
0
Views
60
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote